Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Jan;36(1):311-4.
doi: 10.1128/JCM.36.1.311-314.1998.

Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons

D Brambilla  1 , S Leung, J Lew, J Todd, S Herman, M Cronin, D E Shapiro, J Bremer, C Hanson, G V Hillyer, G D McSherry, R S Sperling, R W Coombs, P S Reichelderfer
Affiliations
Comparative Study

Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons

D Brambilla et al. J Clin Microbiol. 1998 Jan.

Abstract

Use of a common set of human immunodeficiency virus type 1 (HIV-1) RNA standards eliminated differences among absolute HIV-1 RNA copy number estimates made with three commercially available assays. The relative changes in the viral RNA levels determined by the commercial assays were similar and were unaffected by the use of a common set of standards.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Difference between log10 estimated RNA concentrations from the RT-PCR and Chiron ES bDNA assays plotted against the log-transformed mean of the two estimates. A positive difference indicates that the RT-PCR copy number was higher than the Chiron ES bDNA copy number for that patient. a, kit-based copy number estimates; b, VQA-adjusted copy number estimates.
FIG. 2
FIG. 2
Change in log10 RNA concentration as measured by RT-PCR assay versus change in log10 RNA concentration as measured by the Chiron ES bDNA assay. a, kit-based copy number estimates; b, VQA-adjusted copy number estimates. ZDV, zidovudine.
See this image and copyright information in PMC

References

    1. BHIVA Guidelines Co-ordinating Committee. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 1997;349:1086–1092. - PubMed
    1. Carpenter C C J, Fischl M A, Hammer S M, Hirsch M S, Jacobsen D M, Katzenstein D A, Montaner J S G, Richman D D, Saag M S, Schooley R T, Thompson M A, Vella S, Yeni P G, Volberding P A for the International AIDS Society—USA. Antiretroviral therapy for HIV-1 infection in 1996. JAMA. 1996;276:146–154. - PubMed
    1. Connor E M, Sperling R S, Gelber R, Kiselev P, Scott G, O’Sullivan M J, VanDyke R, Bey M, Shearer W, Jacobson R L, Jimenez E, O’Neill E, Bazin B, Delfraissy J, Culnane M, Coombs R, Elkins M, Moye J, Stratton P, Balsley J for The Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173–1180. - PubMed
    1. Coombs R W. HIV-1 burden as a marker of disease progression and clinical response to therapy in AIDS. Clin Lab Med. 1994;14:301–311. - PubMed
    1. Garcia F, Vidal V, Gatell J M, Miro J M, Sorino A, Pumarola T. Viral load in asymptomatic patients with CD4+ lymphocyte counts above 500 × 106/l. AIDS. 1997;11:53–57. - PubMed

Publication types

LinkOut - more resources